Pfizer (PFE) PT Lifted to $41 at BMO Capital on Sum-of-the-Parts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
PFIZER REPORTS SECOND-QUARTER 2015 RESULTS
July 28, 2015 7:00 AM EDTSecond-Quarter 2015 Reported Revenues(1) of $11.9 Billion Second-Quarter 2015 Adjusted Diluted EPS(2) of $0.56, Reported Diluted EPS(1) of $0.42 Raised Midpoints of 2015 Financial Guidance(3) Ranges for Reported Revenues(1) by $500 Million and Reported(1) and Adjusted(2) Diluted EPS by $0.03 and $0.04, Respectively, Due to Strong Performance to Date and Improved Business Outlook Second-Quarter 2015 Reported Revenues(1) for the Innovative Products Business Grew 17% Operationally, Primarily Driven by U.S. Launches of Prevnar 13 Adult and Ibrance
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2015... More
